Clavis to develop companion diagnostic for AML
This article was originally published in Clinica
Norwegian firm Clavis Pharma is to develop a test to detect and quantify human equilibrative nucleoside transporter 1 (hENT1) in acute myeloid leukaemia (AML) patients. The standard drug treatment for AML is cytarabine, but the entry of cytarabine into tumour cells depends on the expression of membrane transporter proteins, particularly hENT1. Clavis Pharma (Oslo, Norway) is developing a derivative of cytarabine called elacytarabine which can be taken up by cells regardless of hENT1 expression level. Thus, patients with low expression of the biomarker may be better treated with Clavis's drug rather than the standard therapy. Development of a flow cytometry test for hENT1 will be funded by a NOK14m ($2.5m) grant Clavis has received from The Research Council of Norway. The grant will cover up to 35% of the total project cost, Clavis says.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.